SEATTLE -- Surgery for pancreatic neuroendocrine tumors (pNETs) significantly improved survival for all patients except those with the earliest-stage disease, a retrospective review of 4,700 patients ...
Two distinct subtypes discovered, each with dramatically different risks of recurrence Patients with more aggressive subtype can be monitored vigilantly for recurrence and possible treatment, while ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SEATTLE -- ...
Effect of BPM 31510 on survival outcomes when used in combination with gemcitabine in a preclinical model of pancreatic cancer. Serum levels of macrophage inhibitory cytokine-1 (MIC1) and matrix ...
Survival trends in chemorefractory unresectable intrahepatic cholangiocarcinoma (ICC) and the effect of yttrium-90 (Y90) radioembolization: SEER versus tertiary cancer center. Second-line gemcitabine ...
A group of researchers funded by Neuroendocrine Tumor Research Foundation (NETRF) has discovered molecular information that may help predict recurrence of non-functional pancreatic neuroendocrine ...
Neuroendocrine tumors (NETs) are rare cancers that can arise in a number of different organs, particularly the gastrointestinal tract, lungs, and pancreas. The clinical course of these tumors can vary ...
A team of department faculty and trainees recently published their research “Prognostic Impact of Tumor Size on Pancreatic Neuroendocrine Tumor Recurrence May Have Racial Variance” in Pancreas.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results